AHA encourages Congressional leaders to pass the Pandemic and All-Hazards Preparedness & Advancing Innovation Act (PAHPAI, S. 2852 & H.R. 6378) before Congress adjourns for 2018.
Letters
Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.
Latest
AHA today urged the United States Pharmacopeial Convention to delay by at least 18 months the effective dates for its general chapter pharmaceutical compounding and general chapter hazardous drug handling in health care settings, as well as proposed revisions to general chapter .
The AHA urges the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
Download the letter (PDF) below
Re: CMS—3346—P, Medicare and Medicaid Programs; Regulatory Provisions To P
AHA shares insights on addressing social risk factors with the Department of Health and Human Services
AHA letter to Congressional leadership expressing support to advance legislation – H.R. 1318/S. 1112 to reduce maternal mortality in the United States.
AHA letter to Treasury Department on Excise Tax on Investment Income of Colleges and Universities.
AHA opposes tariffs that have been imposed on medical equipment and medical products imported from China that are used in hospitals, as well as potential tariffs under consideration that would impact the health care field.
AHA expresses support for the Maternal Health Accountability Act (S. 1112), as amended and passed by the Senate Health, Education, Labor and Pensions Committee in July, and the discussion draft version of the Preventing Maternal Deaths Act of 2018 (H.R. 1318).